Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma

Alicia M. Waters*, Laura L. Stafman*, Evan F. Garner*, Smitha Mruthyunjayappa*, Jerry E. Stewart*, Gregory K. Friedman†, Jennifer M. Coleman‡, James M. Markert‡, G. Yancey Gillespie‡ and Elizabeth A. Beierle*

*Department of Surgery, Division of Pediatric Surgery, University of Alabama, Birmingham, Birmingham, AL, USA 35233; †Department of Pediatrics, Division of Hematology/Oncology, University of Alabama, Birmingham, Birmingham, AL, USA 35233; ‡Department of Surgery, Division of Neurosurgery, University of Alabama, Birmingham, Birmingham, AL, USA 35233

Abstract

Rhabdomyosarcoma (RMS), a tumor of skeletal muscle origin, is the most common sarcoma of childhood. Despite multidrug chemotherapy regimens, surgical intervention, and radiation treatment, outcomes remain poor, especially in advanced disease, and novel therapies are needed for the treatment of these aggressive malignancies. Genetically engineered oncolytic viruses, such as herpes simplex virus-1 (HSV), are currently being explored as treatments for pediatric tumors. M002, an oncolytic HSV, has both copies of the γ134.5 gene deleted, enabling replication in tumor cells but thwarting infection of normal, postmitotic cells. We hypothesized that M002 would infect human RMS tumor cells and lead to decreased tumor cell survival in vitro and impede tumor growth in vivo. In the current study, we demonstrated that M002 could infect, replicate in, and decrease cell survival in both embryonal (ERMS) and alveolar rhabdomyosarcoma (ARMS) cells. Additionally, M002 reduced xenograft tumor growth and increased animal survival in both ARMS and ERMS. Most importantly, we showed for the first time that repeated dosing of oncolytic virus coupled with low-dose radiation provided improved tumor response in RMS. These findings provide support for the clinical investigation of oncolytic HSV in pediatric RMS.

Translational Oncology (2016) 9, 419–430

Introduction

Rhabdomyosarcoma (RMS), a malignant neoplasm of striated muscle, is the most common soft tissue sarcoma of childhood. There are two peaks in incidence, between the ages of 2 to 4 and 12 to 16 years, with the majority diagnosed by age 14 years [1]. The most common primary sites include the head, neck, genitourinary tract, and extremities [2]. The World Health Organization categorizes RMS into embryonal, alveolar, spindle/sclerosing, and pleomorphic subtypes, with embryonal RMS accounting for over 70% of cases and representing the most favorable prognosis [3]. The 5-year survival rate in children diagnosed with low-risk RMS is over 90%. Those with metastatic or recurrent disease, however, fare much worse, with a 5-year survival of only 10% to 20% despite aggressive multimodal therapies [4,5]. This is the group which must be targeted for novel therapies.

The Intergroup Rhabdomyosarcoma Study Group, created in 1972, established clinical trials and standard protocols in efforts to improve outcomes and survival [2]. Current treatment regimens for high-risk RMS include surgery, chemotherapy, and radiation therapy [6]. Oncolytic viruses are currently being explored as treatments for...
Viral Replication

Repeated M002 Dosing Decreases RMS Survival  
Waters et al.

Viral recovery experiments were performed as described previously [12,13]. For single-step viral recovery, RD and SJCRH30 cells were plated and allowed to attach for 24 hours. The cells were infected with M002 at a multiplicity of infection (MOI) of 10 PFU/cell for 2 hours. After 12 and 24 hours, the cells were harvested by adding equal volume of sterile milk and freezing at −80°C. Plates were thawed at 37°C and underwent two more freeze/thaw cycles. Cells and supernatants were collected, milk stocks were sonicated for 30 seconds, and the titers of progeny virions were determined on Vero cell monolayers. The average PFU/ml was calculated from quadruplicate wells.

For multistep viral recovery experiments, RD and SJCRH30 cells were grown to confluence in six-well plates and then infected with M002 at an MOI of 0.1 PFU/cell. The media from the cells were harvested at 6, 24, 48, and 72 hours postinfection. The titers of progeny virions in the supernate were determined as above, and the average PFU/ml was calculated from quadruplicate wells.

ELISA

Production of mIL-12 by the recombinant M002 virus was quantified using a total mIL-12 ELISA kit (Thermo Fisher Scientific, Rockford, IL). Ninety-six–well plates were seeded with 1.5 × 10⁴ cells per well for 24 hours and then treated with media alone or M002. After incubating for 48 hours, the supernates were collected and analyzed by ELISA according to the manufacturer’s protocol.

Virus Cytotoxicity Assays

Cell viability 72 hours after virus treatment in vitro was measured using an alamarBlue assay. Cells were plated (1.5 × 10⁵ cells/100-μl well) in 96-well culture plates and after 24 hours were treated with 100 μl of saline or a graded series of dilutions of M002. After 72 hours of culture, 10 μl of sterile alamarBlue dye (Invitrogen Life Technologies, Grand Island, NY) was added to each well. After 4 to 6 hours, the absorbance at 542 and 595 nm was measured using a kinetic microplate reader (BioTek Gen5; BioTek Instruments, Winooski, VT). Virus cytotoxicity at each dilution was measured by the reduction in the color change compared with that seen in the saline treatment group (100%) viability. These values were plotted to yield an estimate of the PFU of M002 required to inhibit 50% of the cells by 72 hours (IC₅₀/PFU).

Antibodies

Antibodies used for Western blotting were as follows: rabbit polyclonal anti-PVRL-1 (CD111) from Abcam (ab71512; Abcam, Cambridge, MA); rabbit polyclonal anti-nectin 2 (CD122) from Bios (bs2679R; Bios Inc., Woburn, MA); rabbit polyclonal anti-syndecan-2 from LS Biosciences (LS-B2981; LifeSpan Biosciences, Inc., Seattle, WA); rabbit polyclonal anti-phospho Stat1 (Y701, 9171S), anti-Stat1 (9172S), mouse monoclonal anti-phospho-p38 mitogen-activated protein kinase (MAPK) (Thr180/Tyr182, 9216S), and rabbit polyclonal anti-nectin 2 (CD112) from Cell Signaling (Cell Signaling Technology, Inc., Danvers, MA); and rabbit polyclonal anti-p38 (H-147, sc-7149) from Santa Cruz (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Mouse monoclonal anti-β-actin (a1978) was purchased from Sigma (Sigma-Aldrich, St. Louis, MO).

Western Blotting

Western blots were performed as previously described [14]. Cells were lysed on ice for 30 minutes in a buffer containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1% Triton-X, 0.5% NaDOC, 0.1% SDS, 5 mM EDTA, 50 mM NaF, 1 mM NaVO₃, 10% glycerol, and protease inhibitors: 10 μg/ml of leupeptin, 10 μg/ml of PMSF, and 1 μg/ml of aprotinin. The lysates were cleared by centrifugation at 14,000 rpm for 30 minutes at 4°C. Protein concentrations were determined using a Bio-Rad kit (Bio-Rad, Hercules, CA), and
proteins were separated by electrophoresis on SDS-PAGE gels. Antibodies were used according to manufacturers’ recommended conditions. Molecular weight markers (Bio-Rad) were used to confirm the expected size of the target proteins. Immunoblots were developed with chemiluminescence (Amersham ECL; GE Healthcare Biosciences, Pittsburgh, PA). Blots were stripped with stripping solution (Bio-Rad) at 37°C for 15 minutes, rinsed, and then reprobed with selected antibodies. Immunoblotting with antibody to anti–β-actin provided an internal control for equal protein loading.

**Apoptosis**

Cellular apoptosis was detected with two methods; immunoblotting for PARP cleavage and a commercially available colorimetric caspase 3 activation kit (KHZ0022; Invitrogen, Life Technologies, Thermo Fisher Scientific, Inc.). For immunoblotting, cells were treated with increasing MOI of M002 and whole cell lysates utilized for SDS-PAGE. Membranes were probed with appropriate antibodies with β-actin serving as an internal control for equal protein loading. Increasing intensity of PARP bands for cleaved products combined with decreasing intensity of bands for total PARP indicated apoptosis. Additionally, activation of caspase 3 was also measured with a kit, according to manufacturer’s instructions.

**Immunohistochemistry**

Human specimens were obtained following institutional review board (IRB) approval (X100930009) under a waiver of informed consent, and all experiments were carried out in accordance with the IRB-approved guidelines. Formalin-fixed, paraffin-embedded tumor blocks of murine xenografts or human RMS specimens were cut in 8-μm sections. The slides were baked for 1 hour at 70°C, deparaffinized, rehydrated, and steamed. The sections were then quenched with 3% hydrogen peroxide and blocked with PBS-blocking buffer. The primary rabbit polyclonal antibody, anti–herpes simplex virus type I antibody (1:250, PU084-UP; BioGenex, Fremont, CA), or primary mouse polyclonal anti-CD111 antibody (1:300, ab66985, Abcam) was added and incubated overnight at 4°C. After washing the HSV slides with PBS, the Superpicture anti-rabbit HRP secondary antibody (Life Technologies, Inc., Grand Island, NY) was added at 1:250 dilution for 1 hour at 22°C. The staining reaction was developed with VECTASTAIN Elite ABC kit (PK-6100; Vector Laboratories, Burlingame, CA), TSA (biotin tyramide reagent, 1:400; PerkinElmer, Inc., Waltham, MA), and DAB (Metal Enhanced DAB Substrate; Thermo Fisher Scientific). For the CD111 slides, after washing with PBS, the Super Sensitive Polymer-HRP Detection Kit with DAB (QD400-60K; Biogenex, Fremont, CA) was utilized for detection of the antigen-antibody binding. Slides were counterstained with hematoxylin. A negative control (rabbit IgG or mouse IgG, 1 μg/ml [Millipore, EMD Millipore, Billerica, MA]) was included with each experiment. For hematoxylin and eosin staining, slides were cut and baked as described above, and standard hematoxylin and eosin staining methods were utilized.

**Immunohistochemistry Scoring**

Staining for HSV-1 in xenograft tumors was quantified by ImageJ software (http://rsb.info.nih.gov/ij/). Positive HSV-1 staining was reported as percent positive staining cells per high-power field after counting 10 random fields of view per specimen. CD111 staining in human RMS specimens was quantified by pathologist (S. M.) blinded to the specimens. Specimens were scored based upon the intensity of staining and the percentage of tumor cells staining. Intensity was graded from 0 to 3 (0, none; 1, weak; 2, moderate; 3, strong) and multiplied by the percentage of cells with that staining. For example, if the specimen showed moderate staining (2) in 40% of the cells, the stain score would be 80 (2 × 40 = 80).

**Tumor Growth In Vivo**

Animal experiments were completed following institutional institutional animal care and use committee (IACUC) approval (IACUC-09363). Six-week-old female athymic nude mice were purchased from Harlan Laboratories, Inc. (Chicago, IL). The mice were maintained in the specific pathogen free (SPF) animal facility with standard 12-hour light/dark cycles and allowed chow and water ad libitum. All experiments were carried out in accordance with the approved guidelines, and at the completion of the experiments, euthanasia was accomplished according to American Association for Laboratory Animal Science guidelines utilizing compressed CO2 gas in their home cage followed by bilateral thoracotomy. Human RMS cells, RD (2.5 × 10^6 cells), and SJCRH30 (2.0 × 10^6 cells) in Matrigel (1:1 dilution with sterile PBS, volume 100 μl; BD Biosciences, San Jose, CA) were injected subcutaneously into the right flank. Once tumors reached approximately 250 mm³, animals (n = 40) were randomized to receive an intratumoral injection of vehicle (PBS + 10% glycerol, 50 μl) or M002 virus (1 × 10^7 PFU/50 μl) (n = 20). These concentrations were chosen based upon previous investigations with the virus [9,12,13]. Within 6 hours of treatment, half of the vehicle-treated tumors and half of the M002-treated tumors received a low dose of external beam irradiation (3 Gy) directed at the flank tumor (n = 10 animals/group). Previous studies have demonstrated the enhanced oncolytic effects of viral therapy when combined with radiation [15]. Tumors were measured twice weekly with a caliper, and tumor volume in mm³ was calculated using a standard formula [(width^2 × length)/2], where width was the smaller diameter. Once tumors reached the size predetermined by IACUC protocol standards, the animals were euthanized, and the tumors were harvested and processed for study.

For the repeated-dosing study, ARMS SJCRH30 cell line was chosen because ARMS tends to be more difficult to treat than ERMS. SJCRH30 (2.0 × 10^6) cells in Matrigel (1:1 dilution with sterile PBS, volume 100 μl; BD Biosciences) were injected subcutaneously into the right flank of 6-week-old female nude mice (n = 20). Once tumors reached approximately 250 mm³, animals were randomized to receive a single intratumoral injection of M002 virus (1 × 10^7 PFU/50 μl) or an additional two intratumoral doses of virus (1 × 10^7 PFU/50 μl, total of three doses) at 3-day intervals with (n = 7) or without the addition of low-dose flank irradiation (XRT) (n = 7) following the virus injection. Tumors were measured twice weekly with a caliper, and tumor volume in mm³ was calculated using a standard formula [(width^2 × length)/2], where width was the smaller diameter. Once tumors reached the size predetermined by IACUC protocol standards, the animals were euthanized.

**Data Analysis**

Experiments were repeated at least in triplicate, and data are reported as mean ± standard error of the mean. An analysis of variance or Student’s t test was used as appropriate to compare data between groups, and log-rank test was used to determine survival significance. Statistical analyses were completed using SigmaPlot 12 software (SyStat Software, Inc., San Jose, CA) with statistical significance determined at the P ≤ .05 level.
Results

**HSV Entry Receptors and Viral Infectivity**

Two different histologic subtypes of RMS were chosen for study: ERMS (RD) and ARMS (SJCRH30) [16]. CD111 (poliovirus receptor-related protein 1 [nectin-1]) is a cell surface receptor that is the primary viral entry mediator used by HSV-1 for cellular entry [17]. Immunoblotting with CD111 specific antibody detected CD111 protein in whole cell lysates of SJCRH30 and RD RMS cells lines (Figure 1A). Two additional virus entry receptors were also investigated. It has been reported in the literature that certain laboratory strains of HSV-1 may use CD112 (poliovirus receptor-related 2, nectin-2) as another receptor for cell entry [18,19], so we also examined cell lysates for this protein and found that CD112 was also expressed by the SJCRH30 and RD cell lines (Figure 1B). Additionally, heparin sulfate proteoglycan (syndecan-2) is another protein known to play an important role in HSV-1 viral entry and spread [20]. Cell lysates from SJCRH30 and RD cells were examined with immunoblotting and found to have syndecan-2 protein present (Figure 1C). These data indicated that these cell lines had the receptors necessary for HSV-1 viral entry and infection.

In anticipation of advancing to human studies and to provide a rationale for clinical application of oHSV for RMS, we determined whether CD111 protein was present in human RMS specimens. Following IRB approval (X100920009) under a waiver of informed consent, we performed CD111 immunostaining on human RMS (n = 12) and ARMS (n = 10) specimens. The CD111 staining was scored by a pathologist (S. M.) blinded to the specimens, and the mean stain scores were compiled based upon stain intensity. CD111 staining was positive in all of the specimens examined, with a mean stain score of 89 ± 2% in ARMS and 91 ± 1% in RMS specimens. Representative photomicrographs were presented at 10× and 40× (Figure 1, D and E). There was cell surface CD111 staining in both tumor types (Figure 1, D and E, black arrows), and negative controls (rabbit IgG) reacted appropriately (Figure 1, D and E, small box inserts).

To ascertain whether M002 could infect and replicate in the RMS cell lines, *in vitro* replication of M002 was evaluated in the RD and SJCRH30 cell lines using single- and multistep viral recovery experiments. For the single-step experiments, the RD and SJCRH30 cell lines were infected with M002 at an MOI of 10 PFU/cell. By 24 hours postinfection, there were significant viral titers noted in both cell lines (Figure 2A) that continued to increase at 48 hours postinfection (Figure 2A). For multistep viral recovery, monolayers of RD and SJCRH30 cell lines were infected with M002 at an MOI of 0.1 PFU/cell, and at 6, 24, 48, and 72 hours postinfection, viral

![Figure 1](image-url). HSV entry receptors in cell lines and human RMS specimens. (A–C) Immunoblotting with CD111, CD112, and syndecan-2 specific antibodies demonstrated all three proteins to be present in whole cell lysates of SJCRH30 and RD human RMS cell lines. β-Actin was used to confirm equal protein loading. Immunohistochemical staining was performed on human ARMS (D) and ERMS (E) specimens. Representative photomicrographs at 10× and 40× are presented. There was CD111 staining present on the cell surface (black arrows) in both histologic types. Negative controls reacted appropriately (bottom left inserts, D, E).
replication was determined. As shown in Figure 2B, after 72 hours of infection, M002 replicated to a titer significantly higher in both cell lines compared with that of time zero.

Because M002 was genetically engineered to produce mIL-12, to further verify viral infection, we sought to determine the extent to which the infected human RMS cell lines would produce the encoded foreign mIL-12 protein. The RD and SJCRH30 cells were infected with M002 at 0, 0.1, or 1.0 PFU/cell. After 24 hours of infection, the supernates were collected, and an mIL-12 ELISA kit was utilized to detect IL-12 production. There were significant increases in mIL-12 production in both RMS cell lines (Figure 2C), confirming infection and virus replication in both cell lines. In the RD cell line, M002 replicated more than a log higher than control at 72 hours postinfection, and in the SJCRH30 cell line, replication of virus was more than 3 logs greater than time zero. (C) Because M002 was engineered to produce mIL-12, to further verify infection, mIL-12 production was determined in RD and SJCRH30 cell lines following treatment with M002 oHSV. Cell lines were infected with M002 at 0, 0.1, or 1.0 PFU/cell. At 48 hours postinfection, the supernates were collected, and concentrations of mIL-12 were determined by ELISA. Data are reported as mean ± standard error of the mean. There was a significant increase in mIL-12 production in both cell lines even with the lower MOI of virus.

**Figure 2.** Infectivity of M002 in RMS cell lines. (A) Single-step *in vitro* replication of M002. Monolayers of RD and SJCRH30 cells were infected with M002 at an MOI of 10 PFU/cell. Replicate cultures were harvested at 24 and 48 hours postinfection, and virus titers were determined on Vero cell monolayers. Mean virion yields were determined in four replicates at each time point, and standard error of the mean was determined. By 24 hours postinfection, there were significant viral titers noted in both cell lines that continued to increase at 48 hours postinfection. (B) Multistep replication of M002. Monolayers of RD and SJCRH30 cells were infected with M002 at an MOI of 0.1 PFU/cell, and at 6, 24, 48, and 72 hours postinfection, supernates were collected, and virus titers were determined on Vero cell monolayers. Mean virion yields were determined in four replicates at each time point, and standard error of the mean was determined. In the RD cell line, M002 replicated more than a log higher than control at 72 hours postinfection, and in the SJCRH30 cell line, replication of virus was more than 3 logs greater than time zero. (C) Because M002 was engineered to produce mIL-12, to further verify infection, mIL-12 production was determined in RD and SJCRH30 cell lines following treatment with M002 oHSV. Cell lines were infected with M002 at 0, 0.1, or 1.0 PFU/cell. At 48 hours postinfection, the supernates were collected, and concentrations of mIL-12 were determined by ELISA. Data are reported as mean ± standard error of the mean. There was a significant increase in mIL-12 production in both cell lines even with the lower MOI of virus.

Because M002 was genetically engineered to produce mIL-12, to further verify viral infection, we sought to determine the extent to which the infected human RMS cell lines would produce the encoded foreign mIL-12 protein. The RD and SJCRH30 cells were infected with M002 at 0, 0.1, or 1.0 PFU/cell. After 24 hours of infection, the supernates were collected, and an mIL-12 ELISA kit was utilized to detect IL-12 production. There were significant increases in mIL-12 production in both RMS cell lines (Figure 2C), confirming infection and virus replication in both cell lines. In the RD cell line, infection with 0.1 PFU/cell for 24 hours resulted in a concentration of mIL-12 of 2486 ± 100 pg/ml, significantly greater than concentration of 0.0 pg/ml after infection with 0 PFU/cell (control, P = .04) (Figure 2C). In addition, in the SJCRH30 alveolar cell line, increasing the MOI of the M002 oHSV by a factor of 10 resulted in a statistically significant increase in the production of mIL-12 compared with the lower MOI (1194 ± 265 pg/ml vs 5036 ± 636 pg/ml, 0.1 PFU/cell vs 1.0 PFU/cell, P = .03). Previous studies from our group have shown that the parent virus, devoid of mIL-12 insertion, does not stimulate mIL-12 production in human cell lines [9]. The ELISA studies were utilized only to verify virus infection.

**Treatment with M002 Resulted in Cell Death**

RMS cell lines (RD, SJCRH30) were treated for 72 hours with M002 at increasing concentrations (0-20 PFU/cell), and cell viability was measured with alamarBlue assays. Both cell lines had a significant decrease in viability following M002 treatment (Figure 3A). The lethal dose of virus that resulted in 50% killing (LD<sub>50</sub>) for the embryonal RD cells was 3.3 ± 0.1 PFU/cell and for the alveolar SJCRH30 cells was 4.1 ± 0.4 PFU/cell.
Next, we investigated whether the viral-induced cell death was due to apoptosis. RD and SJCRH30 cell lines were treated with increasing concentrations of M002 (0-10 PFU/cell), and whole cell lysates were collected after 72 hours of treatment. Lysates were studied with immunoblotting to detect cleavage of PARP. The decrease in total PARP, accompanied with an increase in the cleaved PARP product, indicated that the RMS cells were undergoing apoptosis. This finding was evident in both cell lines (Figure 3B). Apoptosis was confirmed using a caspase 3 activation kit. There was a significant increase in caspase 3 activation in the SJCRH30 cell line at 0.1 PFU/cell and in the RD cell line at MOI of 10 PFU/cell (Figure 3C), similar to the results seen in the PARP immunoblotting, indicating an apoptotic process.

**In Vivo Tumor Studies**

All experiments were performed in accordance with relevant guidelines and regulations after IACUC approval (IACUC-09,363). To determine the *in vivo* effects of M002 treatment on RMS, nude mouse xenograft models were utilized. RD human ERMS cells (2.5 × 10^6 in Matrigel [BD Biosciences]) were injected subcutaneously into the right flank of female athymic nude mice (*n* = 40). Once flank tumors reached an average volume of 250 mm³, the tumors were injected with either control vehicle (PBS + glycerol, 50 μl, *n* = 20) or a single dose of M002 (1 × 10⁷ PFU/50 μl, *n* = 20). Because the addition of low dose radiation has been shown to increase the activity of oHSV in malignant gliomas [15,21,22], we examined whether the addition of a single low dose of radiation would also enhance the efficacy of M002 in the RD xenografts. Therefore, half of the animals in each group received a low dose of irradiation to the tumor immediately following injection with vehicle or M002. Three grays (3 Gy, XRT) was chosen because other investigations have shown that HSV replication increased in a dose-dependent fashion following irradiation with 2 to 5 Gy, with no additional effects seen after 5 Gy [22]. Tumor volumes were measured biweekly with calipers. Tumor volumes were followed 40 days, when most of the vehicle-treated animals had been euthanized as dictated by IACUC protocol. In the animals treated with M002 and XRT, there was a significant decrease in tumor growth beginning at day 19 and continuing to 40 days when compared with the animals in the vehicle or vehicle + XRT treatment groups (*P* ≤ .05) (Figure 4A). Tumor volumes in the M002 + XRT were also smaller than those from M002 alone but did not reach statistical significance. The addition of low-dose (3 Gy) XRT to the vehicle treatment did not significantly affect tumor growth when compared with vehicle alone (Figure 4A). Animals were followed for

![Figure 3](image-url)

**Figure 3.** Treatment with M002 resulted in cell death. (A) RD and SJCRH30 cell lines were treated with M002 at increasing MOI. After 72 hours of treatment, cell viability was measured with alamarBlue assays. Data are reported as mean ± standard error of the mean. There was a significant decrease in viability in both cell lines following M002 treatment. The LD₅₀ was calculated for each cell line for M002 and was 3.3 ± 0.1 PFU/cell for embryonal RD cells and 4.1 ± 0.4 PFU/cell for the alveolar SJCRH30 cells. (B) To determine whether RMS cells were undergoing an apoptotic process following M002 treatment, immunoblotting for cleavage of PARP was completed. There was a significant decrease in total PARP staining and an increase in cleaved PARP staining in both cell lines with increasing MOIs. (C) To further verify apoptosis, a caspase 3 activation kit was utilized. There was a significant increase in caspase 3 activation following M002 treatment, indicating that the RMS cells were undergoing an apoptotic process.
survival, and tumors were weighed at the time of euthanasia. RD xenograft tumors treated with M002 + XRT weighed significantly less than those treated with vehicle or vehicle + XRT (1.9 ± 0.3 g vs 3 ± 0.3 g or 2.8 ± 0.3 g, M002 + XRT versus vehicle or vehicle + XRT, \( P \leq .02 \)) (Figure 4B). The M002 + XRT tumors also weighed less than those treated with M002 alone but, similar to tumor volume, did not reach significance (Figure 4B). There were some differences in the final weights of the animals at the time of euthanasia, but these were not statistically significant (Figure S1A). To exclude animal growth as an explanation for differences in tumor weights, tumor to body weight ratios at the time of animal euthanasia were calculated. These ratios (Figure S1B) were consistent with the data seen with tumor weights alone, discounting animal growth as a factor in tumor weight differences. As seen in Figure 4C, the animals treated with M002 had significantly increased survival when compared with vehicle-treated animals (36.3 ± 3.0 vs 27.2 ± 2.1 days, M002 versus vehicle, \( P = .017 \)). In addition, animals treated with M002 + XRT had significantly increased survival over those treated with vehicle or vehicle + XRT (Figure 4C).

The second set of in vivo experiments examined the effects of M002 upon SJCRH30 ARMS xenografts. SJCRH30 cells (2.0 × 10^6 cells in Matrigel [BD Biosciences]) were injected into the subcutaneous space of the right flank of female nude mice \( (n = 40) \). Once xenografts reached 250 mm^3, tumors were injected with vehicle (PBS + glycerol, 50 μl) or a single dose of M002 (1 × 10^7 PFU/50 μl, \( n = 20 \)). Half of the animals in each group also received low-dose irradiation (3 Gy) at the time of injection. Tumor volumes were measured twice weekly \([\text{width}]^2 \times \text{length}/2\) for 40 days. Data are reported as tumor volume ± standard error mean. In the animals treated with M002 and XRT, there was a significant decrease in tumor growth beginning at day 19 when compared with the animals in the vehicle or vehicle + XRT treatment groups. Tumor volumes in the M002 + XRT were also smaller than those from M002 alone, but this did not reach statistical significance. The addition of low-dose (3 Gy) XRT to the vehicle treatment did not significantly affect tumor growth (Figure 3A). (B) Xenograft tumors were weighed at euthanasia. There was a significant decrease in tumor weight in the animals treated with M002 and XRT when compared with animals that received vehicle alone or vehicle with XRT. Tumor weights in M002 + XRT group tended to be less than those of M002 alone but did not reach statistical significance. Lines in bars represent the median, and the whiskers represent the 5th and 95th percentile. (D) Kaplan-Meier curves were constructed with log-rank statistics to evaluate animal survival. Animals treated with M002 had significantly increased survival over those treated with vehicle alone. Animals treated with M002 + XRT also had a significant survival advantage when compared with those treated with vehicle or vehicle + XRT.

Figure 4. M002 treatment of RD xenografts. (A) RD human RMS tumor cells (2.5 × 10^6 cells) were injected into the right flank of athymic nude mice. Once tumors reached a volume of 250 mm^3, animals received an intratumoral injection of vehicle (PBS + 10% glycerol, 50 μl \( [n = 20] \)) or M002 virus (1 × 10^7 PFU/50 μl \( [n = 20] \)). Half of the animals in each group also received low-dose irradiation (3 Gy) at the time of injection. Tumor volumes were measured twice weekly \([\text{width}]^2 \times \text{length}/2\) for 40 days. Data are reported as tumor volume ± standard error mean. In the animals treated with M002 and XRT, there was a significant decrease in tumor growth beginning at day 19 when compared with the animals in the vehicle or vehicle + XRT treatment groups. Tumor volumes in the M002 + XRT were also smaller than those from M002 alone, but this did not reach statistical significance. The addition of low-dose (3 Gy) XRT to the vehicle treatment did not significantly affect tumor growth (Figure 3A). (B) Xenograft tumors were weighed at euthanasia. There was a significant decrease in tumor weight in the animals treated with M002 and XRT when compared with animals that received vehicle alone or vehicle with XRT. Tumor weights in M002 + XRT group tended to be less than those of M002 alone but did not reach statistical significance. Lines in bars represent the median, and the whiskers represent the 5th and 95th percentile. (D) Kaplan-Meier curves were constructed with log-rank statistics to evaluate animal survival. Animals treated with M002 had significantly increased survival over those treated with vehicle alone. Animals treated with M002 + XRT also had a significant survival advantage when compared with those treated with vehicle or vehicle + XRT.
significantly smaller tumor volumes than the animals from the other three treatment groups, including M002 alone (Figure 5A). The addition of low-dose (3 Gy) XRT to the vehicle treatment did not affect SJCRH30 tumor growth compared with vehicle alone (Figure 5A). The animals remaining were followed for survival. At euthanasia, tumors were harvested and weighed. M002 + XRT–treated SJCRH30 xenografts tended to weigh less than those of the other treatment groups, but this difference reached statistical significance only when compared with the vehicle + XRT treatment group (Figure 5B). As seen with the RD xenografts, there were some differences in the final weights of the animals at the time of euthanasia, but these were not statistically significant (Figure 5C). Tumor to body weight ratios at the time of animal euthanasia were calculated, and these ratios (Figure S1D) were consistent with the data seen with tumor weights alone, discounting animal growth as a factor in tumor weight differences. Animals treated with M002 alone had improved mean survival over animals treated with vehicle alone (41.4 ± 3.6 vs 32.3 ± 2.7 days, M002 versus vehicle, \(P = .05\)) as depicted in Figure 5C. Furthermore, animals treated with M002 + XRT had an increase in survival over those treated with vehicle alone or with vehicle + XRT (Figure 5C). The notable decreases in tumor volume with the addition of XRT to M002 treatment (Figure 5A) did not translate into statistically improved survival advantage over M002 alone (54.4 ± 7.3 vs 41.4 ± 3.6 days, \(P = .3\), M002 + XRT versus M002, Figure 5C). In both cell types, tumor growth was significantly decreased but not completely abrogated.

The presence of HSV in the tumors following treatment was verified with immunohistochemical staining for HSV-1. Representative photomicrographs are presented in Figure 6. Immunohistochemical staining for HSV-1 detected virus in tumors injected with M002 (Figure 6, middle panel brown stain, white arrows) and with M002 + XRT (Figure 6, lower panel brown stain, white arrows) for up to 7 days post virus injection. There was a lack of staining in tumors injected with vehicle (Figure 6, upper panel). Negative controls

---

**Figure 5.** M002 treatment of SJCRH30 xenografts. (A) SJCRH30 cells (2.0 × 10⁶ cells) were injected into the subcutaneous space of the right flank of female nude mice (n = 40). Once tumors reached 250 mm³, animals received an intratumoral injection of vehicle (PBS + 10% glycerol, 50 μl [n = 20]) or M002 virus (1 × 10⁷ PFU/50 μl [n = 20]). Half of each group was also treated with 3-Gy external beam radiation at the time of injection (XRT). Tumor volumes were measured twice weekly and reported as tumor volume ± standard error. Beginning on day 23, there was a significant decrease in tumor volume in the animals treated with combined M002 + XRT. (B) Xenograft tumors were weighed at euthanasia. There was a significant decrease in tumor weight in the animals treated with M002 and XRT when compared with animals that received vehicle with XRT. Lines in bars represent the median, and the whiskers represent the 5th and 95th percentile. (C) Kaplan-Meier curves were constructed with log-rank statistics to examine animal survival. Animals treated with M002 had significantly increased survival over those treated with vehicle alone. Animals treated with M002 + XRT also had a significant survival advantage when compared with those treated with vehicle or vehicle and XRT.
reacted appropriately (Figure 6, insert bottom right upper, middle, and lower panels). Immunohistochemical staining was quantified with ImageJ software. There was a slight increase in the amount of positive staining at 7 days postinfection when comparing tumors treated with M002 + XRT versus those treated with M002 alone, but this finding was not statistically significant.

Because M002 did not result in a sustained response in decreasing tumor growth, we advanced to a model of repeated dosing of virus. We chose to study the SJCRH30 cell line because ARMS is clinically more difficult to treat. SJCRH30 cells (2.0 × 10^6 cells in Matrigel [BD Biosciences]) were injected into the subcutaneous space of the right flank of female nude mice (n = 20). Once xenografts reached

**Figure 6.** Histological examinations of RMS xenografts for HSV. The presence of HSV in the tumors following treatment was verified with immunohistochemical staining for HSV-1. Representative photomicrographs are at 20× (right) and 40× (left). Immunohistochemical staining for HSV-1 detected virus in tumors injected with M002 (middle panels brown stain, white arrows) and M002 + XRT (bottom panels brown stain, white arrows), present at 7 days post virus injection. Tumors injected with vehicle did not demonstrate HSV staining (upper panels). Negative controls reacted appropriately (insert, bottom right, upper, middle, and lower panels).
250 mm$^3$, animals were randomized to three treatment groups: 1) a single intratumoral injection of M002 on day 0 ($1 \times 10^7$ PFU/50 μl, $n = 6$); 2) repeated intratumoral injection of M002 on days 0, 3, and 6 ($1 \times 10^7$ PFU/50 μl, $n = 7$); or 3) repeated intratumoral injection of M002 ($1 \times 10^7$ PFU/50 μl) on days 0, 3, and 6 with low-dose XRT (3 Gy) on those days ($n = 7$). Tumor volumes were measured twice weekly and followed for 40 days when most of the single-dose animals had been euthanized per IACUC protocol. Animals treated with repeated doses of M002 had significantly smaller tumor volumes than the animals that received only a single dose of virus (Figure 7). Furthermore, animals that were given low-dose XRT in addition to repeat M002 had smaller tumors than those that did not receive additional XRT and those that had only a single intratumoral injection of M002 (Figure 7).

**STAT1 and p38 MAPK**

We investigated possible mediators of sensitivity of the two RMS cell lines to M002. Previous investigators have shown that upregulation of STAT1 was associated with decreased response to oHSV [23]. Other investigators have shown that decreased phosphorylation of p38 was also associated with resistance to oHSV and that increased activation of p38 MAPK was associated with improved virus replication [21,23,24]. Therefore, to determine if these proteins played a potential role in the difference in responses of these proteins, we investigated if increased activation of p38 MAPK was associated with resistance to oHSV [23]. Other investigators have shown that decreased upregulation of STAT1 was associated with decreased response to oHSV [23]. Others have shown that decreased phosphorylation of p38 was also associated with resistance to oHSV and that increased activation of p38 MAPK was associated with improved virus replication [21,23,24]. Therefore, to determine if these proteins played a potential role in the difference in responses of these proteins, we investigated if increased activation of p38 MAPK was associated with resistance to oHSV [23].

**Discussion**

Despite therapeutic advances in the treatment of RMS, advanced stage and recurrent tumors continue to carry a dismal prognosis with little chance for long-term survival. Clearly, novel therapeutic interventions are needed to combat this cancer, and various virotherapies including vaccinia virus, picornavirus, and herpes simplex viruses have been investigated as alternative treatments for these tumors. He and colleagues utilized a recombinant vaccinia oncolytic virus and demonstrated 40% cytotoxicity in the RMS cell line HTB-82 7 days after infection with an MOI of 5 [8]. Others examined the effects of Seneca Valley virus, NTX-010, against RMS. Two of the four RMSs had an IC$_{50}$ less than 1 virus particle per cell, and NTX-010 inhibited the growth of four alveolar RMS xenografts in vivo [25]. Data regarding the ability of oHSV to target human RMS are sparse. Currier and colleagues studied the effects of a first-generation mutated HSV (NV-1020) upon two RMS cell lines. They found that with multiple injections of virus, the growth of both ARMS and ERMS xenografts was significantly decreased [26]. Pressey et al. demonstrated that ARMS and ERMS cell lines contained myogenically primitive cells marked by CD133 that had cancer stem cell features and were resistant to several chemotherapy agents but were sensitive to oHSV in vitro [27]. These previous studies supported our investigations of the oHSV M002 in RMS.

Although virotherapy alone may be a viable therapeutic option for RMS, modifications, such as the addition of exogenous cytokines, could further contribute to the antitumor effects. The oHSV utilized in these studies, M002, was encoded with the gene for mIL-12 [9], and the levels of IL-12 that were produced by both cell lines were over several nanograms per milliliter. IL-12 is best known as a cytotoxic T-lymphocyte and NK cell activator but also has antitumor effects on RMS. Low serum levels of IL-12 have been correlated with advanced disease, decreased response to chemotherapy, and poor outcome in children with soft tissue sarcomas [28]. Schilbach and others utilized humanized mice to study the effects of IL-12 administration upon human RMS and showed that treatment with an antibody–IL-12 fusion protein arrested cancer cell proliferation and induced myogenic differentiation in the tumors [29]. In the current studies, we investigated oHSV on human RMS cell lines, thereby requiring the use of immunodeficient mice. We were not able to determine the immunologic effects of IL-12 in these xenografts because these mice have negligible immune cells. The precise contribution of IL-12 to the effects of oHSV seen upon RMS cell lines in these studies will certainly be the subject of future investigations.

A novel aspect of the current data is the documentation that both ARMS and ERMS express the CD111 viral entry molecule, lending credence to translating this therapy to the clinical setting. Another important finding was that both ARMS and ERMS cell lines have multiple oHSV viral entry receptors present. Although the expression of CD111 in RMS cell lines has been documented [27], to our knowledge, the demonstration of other important HSV entry receptors has not been previously reported in the literature for these cell lines. The relative expression of these receptors did not significantly affect the ability of M002 to infect the cells. For example, CD111 expression was less in the SJCRH30 compared with the RD cell line, but single and multistep viral infection studies demonstrated similar if not improved infection in the SJCRH30 compared with the RD cell line. In addition, despite lower levels of CD111 protein in the SJCRH30 cell line, M002 was still very
effective at cell killing, and this may be due to the availability of other viral entry proteins such as CD112 and syndecan-2. These findings are consistent with those seen recently with neuroblastoma. Wang and colleagues found that the sensitivity of neuroblastoma cell lines to herpes simplex viruses by ionizing radiation: a new paradigm for destruction of recurrent glioblastoma. Proc Natl Acad Sci U S A 97, 2208–2213.

Chou J, Kern ER, Whitley RJ, and Roizman B (1999). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in human neuroblastoma. Neuro Oncol 18, 227–235.

Gilloy LA, Megison ML, Stewart JE, Mroczek-Musulman E, Nabers HC, Waters AM, Kelly V, Coleman JM, Markert JM, and Gillespie GY, et al. (2013). Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. PlaS One 8, e77753.

Gillespie GY, Clavelin L, (2015). Cell cycle 9, 1005–1015.

Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B, and Weichselbaum RR (1998). Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically tractable tumors. Gene Ther 5, 160–165.

Huerst-Martinez J, Rello-Vazona S, Herroto-Martín D, Barrau I, García-Monclús S, Sáinz-Jaspeado M, Lagares-Tena L, Núñez-Álvarez Y, Mateo-Lozano S, and Mora J, et al. (2014). Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth. Oncotarget 5, 9744–9755.

Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM, and Gillespie G (2009). Engineered herpes simplex viruses efficiently infect and kill human glioma xenograft cells that express CD111. J Neurooncol 95, 199–209.

Krummenacher C, Baribaud F, Ponse de Leon M, Baribaud I, Whiteck JC, Xu R, Cohen GH, and Eisenberg RJ (2004). Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virol 322, 286–299.

Wang PY, Swain HM, Kunkler AL, Chen CY, Hutzen BJ, Arnold MA, Streeby KA, Collins MH, Dipasquale B, and Stanek JR, et al (2016). Neuroblastomas

Acknowledgements

This work was funded in part by a grant from the National Cancer Institute (T32CA091078; A. M. W., L. L. S., E. F. G). The content of this manuscript was solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. *Gene Ther* **23**, 135–143.

[20] Bacsa S, Karasneh G, Dosa S, Liu J, Valyi-Nagy T, and Shukla D (2011). Syndecan-1 and syndecan-2 play key roles in herpes simplex virus type-1 infection. *J Gen Virol* **92**, 733–743.

[21] Mezhir JJ, Advani SJ, Smith KD, Darga TE, Poon AP, Schmidt H, Posner MC, Roizman B, and Weichselbaum RR (2005). Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. *Cancer Res* **65**, 9479–9484.

[22] Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, and Weichselbaum RR (2011). Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. *Gene Ther* **18**, 1098–1102.

[23] Mahller YY, Sakhivel B, Baird WH, Aronow BJ, Hsu YH, Cripe TP, and Mehrian-Shai R (2008). Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication. *Cancer Gene Ther* **15**, 733–741.

[24] Friedman GK, Nan L, Haas MC, Kelly VM, Moore BP, Langford CP, Xu H, Han X, Beierle EA, and Markert JM, et al (2015). γ34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. *Gene Ther* **22**, 348–355.

[25] Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, and Smith MA (2010). Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. *Pediatr Blood Cancer* **55**, 295–303.

[26] Currier MA, Adams LC, Mahller YY, and Cripe TP (2005). Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. *Cancer Gene Ther* **12**, 407–416.

[27] Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY, and Friedman GK, et al (2013). CD153 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. *Pediatr Blood Cancer* **60**, 45–52.

[28] Bien E, Krawczyk M, Izycka-Swieszewska E, Trzonkowski P, Kazanowska B, Adamkiewicz-Drozynska E, and Balcarska A (2013). Deregulated systemic IL-10/IL-12 balance in advanced and poor prognosis paediatric soft tissue sarcomas. *Biomarkers* **18**, 204–215.

[29] Schilbach K, Alkhaleed M, Welker C, Eckert F, Blank G, Ziegler H, Sterk M, Muller F, Sonntag K, and Wieder T, et al (2015). Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. *Oncoimmunology* **4**, e1014760.

[30] Dai MH, Zamarin D, Gao SP, Chou TC, Gonzalez L, Lin SF, and Fong Y (2010). Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. *Br J Surg* **97**, 1385–1394.

[31] Adusumilli PS, Chan MK, Hezel M, Yu Z, Stiles BM, Chou TC, Rusch VW, and Fong Y (2007). Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. *Ann Surg Oncol* **14**, 258–269.

[32] Adusumilli PS, Stiles BM, Chan MK, Chou TC, Wong RJ, Rusch VW, and Fong Y (2005). Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. *Ann Thorac Surg* **80**, 409–416.

[33] Blank SV, Rubin SC, Cokus G, Amin KM, Albeda SM, and Molnar-Kimber KL (2002). Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. *Hum Gene Ther* **13**, 627–639.

[34] Chung SM, Advani SJ, Bradley JD, Kataoka Y, Vashistha K, Yan SY, Markert JM, Gillespie GY, Whiteley RJ, Roizman B, and Weichselbaum RR (2002). The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. *Gene Ther* **9**, 75–80.